Market Overview

Morgan Stanley Sees Possible Good Things Ahead For Medtronic

Related MDT
Medtronic Completes Acquisition of Twelve, Inc.
Medtronic Initiates Global Study of Minimally Invasive Technology to Aid Lung Cancer Diagnosis

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).

In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”

Medtronic closed on Thursday at $59.43.

Latest Ratings for MDT

Sep 2015JefferiesMaintainsHold
Sep 2015Cowen & CompanyMaintainsOutperform
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (MDT)

Get Benzinga's Newsletters